Oral Surgery in Patients Taking Direct Oral Anticoagulants (DOACs): A Practical Review of the Literature
DOI:
https://doi.org/10.12974/2311-8695.2019.07.2Keywords:
DOACs, Coagulation, Surgery, Peri-operative planning.Abstract
Recently, four new oral anticoagulant – dabigatran etexilate (direct thrombin inhibitor) and rivaroxaban, apixaban and edoxaban (Xa factor direct inhibitor) – have been approved for the prevention of venous thrombosis and cardiovascular events. As the number of patients taking these drugs is increasing, it is important that the dentist is familiar with these new oral anticoagulants, their indications, methods of action and in particular the management of the patients undergoing oral surgery.
This literature review is conducted to highlight the medical uses of these new oral anticoagulants and their pharmacologic properties, the clinical condition of the patient that may influence the choice to discontinue the DOAC and peri-operative management of the patient. Collaboration with the attending physician is crucial.
References
Poulakos M, Walker JN, Baig U, David T. Edoxaban: A direct oral anticoagulant. Am J Heal Pharm 2017. https://doi.org/10.2146/ajhp150821
Miranda M, Martinez LS, Franco R, Forte V, Barlattani AJ, Bollero P. Differences between warfarin and new oral anticoagulants in dental clinical practice. Oral Implantol (Rome) 2016; 9: 151-6. https://doi:10.11138/orl/2016.9.3.151
Wienen W, Stassen J-M, Priepke H, Ries UJ, Hauel N. Invitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007. https://doi.org/10.1160/TH07-03-0183
Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002. https://doi.org/10.1021/jm0109513
Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007. https://doi.org/10.1111/j.1365-2125.2007.02899.x
Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008; 28: 380-6. https://doi.org/10.1161/ATVBAHA.108.162677
Stangier J, Clemens A. Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor. Clin Appl Thromb 2009. https://doi.org/10.1177/1076029609343004
Firriolo FJ, Hupp WS. Beyond warfarin: The new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol 2012. https://doi.org/10.1016/j.oooo.2011.10.005
Food and Drug Administration. Approved drug label n.d. http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/2 02439s029lbl.pdf (accessed June 10, 2019).
Hanken H, Gröbe A, Heiland M, Smeets R, Kluwe L, Wikner J, et al. Postoperative bleeding risk for oral surgery under continued rivaroxaban anticoagulant therapy. Clin Oral Investig 2016. https://doi.org/10.1007/s00784-015-1627-9
Eriksson B, Dahl O, Rosencher N, Kurth A. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total …. Lancet 2007.
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost 2007. https://doi.org/10.1111/j.1538-7836.2007.02748.x
Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery. J Arthroplasty 2009. https://doi.org/10.1016/j.arth.2008.01.132
Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008. https://doi.org/10.1177/0091270008324179
Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol 2010; 85: 185-7. https://doi.org/10.1002/ajh.21607
Carlsson SC, Mattsson C, Eriksson UG, Sarich TC, Wåhlander K, Eliasson Å, et al. A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thromb Res 2005. https://doi.org/10.1016/j.thromres.2004.07.001
Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008. https://doi.org/10.2165/00003088-200847010-00005
Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008. https://doi.org/10.1124/dmd.107.019083
Mehta RS. Novel oral anticoagulants. Part II: Direct thrombin inhibitors. Expert Rev Hematol 2010. https://doi.org/10.1586/ehm.10.12
Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and In vivo P-Glycoprotein Transport Characteristics of Rivaroxaban. J Pharmacol Exp Ther 2011. https://doi.org/10.1124/jpet.111.180240
Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007; 63: 469-76. https://doi.org/10.1111/j.1365-2125.2006.02776.x
Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman M V., Kakkar AK, et al. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty. N Engl J Med 2008. https://doi.org/10.1056/NEJMoa0800374
Cocero N, Basso M, Grosso S, Carossa S. Direct Oral Anticoagulants and Medical Comorbidities in Patients Needing Dental Extractions: Management of the Risk of Bleeding. J Oral Maxillofac Surg 2019. https://doi.org/10.1016/j.joms.2018.09.024
Gómez-Moreno G, Fernández-Cejas E, Aguilar-Salvatierra A, de Carlos F, Delgado-Ruiz RA, Calvo-Guirado JL. Dental implant surgery in patients in treatment by dabigatran. Clin Oral Implants Res 2018. https://doi.org/10.1111/clr.12785
Gómez-Moreno G, Aguilar-Salvatierra A, Fernández-Cejas E, Delgado-Ruiz RA, Markovic A, Calvo-Guirado JL. Dental implant surgery in patients in treatment with the anticoagulant oral rivaroxaban. Clin Oral Implants Res 2016. https://doi.org/10.1111/clr.12653
Rodriguez y Baena R, Beltrami R, Tagliabo A, Rizzo S, Lupi SM. Differences between panoramic and Cone Beam-CT in the surgical evaluation of lower third molars. J Clin Exp Dent 2017. https://doi.org/10.4317/jced.53234
Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate - A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010. https://doi.org/10.1160/TH09-11-0758
